The University of California (UC), San Diego Medical Center has been announced as a new clinical site for the INSPIRE study. Joseph Ciacci, clinical professor of Surgery at the UC San Diego School of Medicine and chief of Neurosurgery at the Veteran Affairs San Diego Healthcare System, has been named principal investigator at the site.
The INSPIRE (InVivo study of probable benefit of the Neuro-Spinal Scaffold for safety and neurologic recovery in subjects with complete thoracic AIS A spinal cord injury) study’s new site is located in Hillcrest, USA, has 390 beds, and is one of only two Level I Trauma Centers in San Diego County.
UC San Diego Medical Center, located in Hillcrest, has 390 beds and is one of only two Level I Trauma Centers in San Diego County.
“My team and facility are well-suited for a clinical trial in this area. I look forward to being a part of this study,” says Ciacci.
Mark Perrin, InVivo’s chief executive officer and chairman, says, “Ciacci and the team at the UC San Diego Medical Center serve as a valuable addition to our clinical network for The INSPIRE Study.”
There are now 15 US clinical sites participating in the clinical study:
- Banner University Medical Center, Tucson
- Barnes-Jewish Hospital at Washington University Medical Center, St. Louis
- Barrow Neurological Institute – St. Joseph’s Hospital and Medical Center, Phoenix
- Carolina Neurosurgery and Spine Associates/Carolinas Rehabilitation, Charlotte
- Cooper Neurological Institute, Camden
- Goodman Campbell Brain and Spine /Indiana University Health Neuroscience Center, Indianapolis
- Keck Hospital of University of Southern California, Los Angeles
- Medical College of Wisconsin/Froedtert Hospital, Milwaukee
- Mount Sinai Hospital, New York
- Oregon Health & Science University, Portland
- Rutgers New Jersey Medical School, Newark
- University of California, Davis Medical Center, Sacramento
- University of California, San Diego Medical Center, San Diego
- University of Kansas Medical Center, Kansas City
- University of Pittsburgh Medical Center Presbyterian, Pittsburgh
The US ClinicalTrials.gov website identifies this study by the code NCT02138110
